| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) financing activities | -102,359 | 31,771 |
| Net decrease in cash and cash equivalents | -18,220,873 | 21,252,090 |
| Cash and cash equivalents at beginning of period | 56,490,579 | - |
| Cash and cash equivalents at end of period | 38,269,706 | - |
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)